Abstract
Ovarian cancer is characterized by frequent mutations at TP53. These tumors also harbor germline mutations at homologous recombination repair (HR) genes, so they rely on DNA-damage checkpoint proteins, like the Checkpoint kinase 1 (CHEK1) to induce G2 arrest. In our study, by using an in silico approach, we identified a synthetic lethality interaction between CHEK1 and mitotic Aurora Kinase A (AURKA) inhibitors. Gene expression analyses were used for the identification of relevant biological functions. OVCAR3, OVCAR8, IGROV1 and SKOV3 were used for proliferation studies. Alisertib was tested as AURKA inhibitor and LY2603618 as CHEK1 inhibitor. Analyses of cell cycle and intracellular mediators were performed by flow cytometry and Western blot.
Impact on stem cell properties was evaluated by flow cytometry analysis of surface markers and sphere formation assays. Gene expression analyses followed by functional annotation identified a series of deregulated genes which belonged to cell cycle, including AURKA/B, TTK kinase and CHEK1. AURKA and CHEK1 were amplified in 8.7% and 3.9% of ovarian cancers, respectively. AURKA and CHEK1 inhibitors showed a synergistic interaction in different cellular models. Combination of Alisertib and LY2603618 triggered apoptosis, reduced the stem cell population and increased the effect of taxanes and platinum compounds. Finally, expression of AURKA and CHEK1 was linked with detrimental outcome in patients. Our data describes a synthetic lethality interaction between CHEK1 and AURKA inhibitors with potential translation to the clinical setting.
Introduction

Identification of druggable vulnerabilities is a main goal in oncogenic diseases
where available therapies can only slightly prolong survival [1, 2] . Even though new therapies can reduce and delay tumor growth, most cancers become resistant, with the appearance of new clones of cells that are insensitive to the inhibited mechanisms [3] .
Advanced ovarian cancer represents an important clinical problem since limited benefit can be obtained from available therapies [4] . In this context, it is mandatory to identify druggable mechanisms that are responsible for the oncogenic phenotype and that can augment the effectiveness of existing therapies.
The classical treatment in ovarian cancer includes anti-mitotic agents like taxanes in combination with DNA damaging agents like platinum compounds [4] . Recently, new agents have been incorporated to the therapeutic armamentarium including anti-angiogenic compounds such as the antibody bevacizumab or agents targeting DNA repair mechanisms like PARP inhibitors, among others [4] [5] [6] .
Several molecular alterations have been described in ovarian cancer including, uncontrolled regulation of mitosis, deficiencies in DNA damage repair mechanisms or activation of intracellular pathways involved in proliferation and survival [7, 8] . In this context, some mitotic protein kinases have been identified as upregulated and linked to worse outcome in ovarian cancer, constituting potential therapeutic targets [9] . Drugs against mitotic kinases like Polo-like kinases (PLK), Never in mitosis (NIMA) or Aurora kinases (AURK) have been recently described [10] . Moreover, massive genomic studies have reported overexpression of some of these proteins in ovarian carcinoma [11] . Indeed, agents against some of these proteins, such as those targeting AURKs are currently in clinical development [12, 13] .
Control of DNA damage is a key function associated with the initiation and maintenance of ovarian cancer [14] . Genetic studies have reported frequent mutations in TP53 in high grade serous ovarian carcinoma [11] . Moreover, germline mutations at the homologous recombination repair genes BRCA1 and BRCA2 predispose to ovarian cancer and are currently used to identify tumors susceptible to be treated with PARP inhibitors [5] . Both functions, cell cycle control and DNA repair, are mechanistically linked as cells that have a high proliferation rate acquire more genetic instability, and supervision of DNA lesions and repair becomes more difficult [14] . Among the different proteins involved in the regulation and identification of DNA damage, the Checkpoint kinase 1 (CHEK1) is a key member [15] . It mediates cell cycle arrest in response to DNA damage by integrating the signals from ATM and ATR [15] . In addition, some mitotic kinases like Aurora or PLK are involved in the regulation of the DNA damage response through the phosphorylation of cell cycle regulators [16, 17] .
In this context, targeting of DNA repair mechanisms in combination with inhibition of key regulators of the mitotic process could be an exploitable path to treat ovarian cancer.
In this article by using an in silico approach we identify Aurora Kinases A and B (AURKA and AURKB) and CHEK1 as an upregulated family of genes in ovarian cancer. Together AURKA and CHEK1 were amplified in around 12% of ovarian tumors. We show that inhibition of AURKA synergized with the inhibition of the DNA repair regulator CHEK1. The combined inhibition induced cell cycle arrest, apoptosis and synergized with chemotherapies, having also an effect on populations of cells with stem cell properties. In addition, the concomitant expression of these genes was linked to poor clinical outcome.
Taking together the data contained in our article paves the way for future preclinical studies and exploratory early phase clinical trials using this combination.
Material and Methods
Transcriptomic analysis, functional annotation and outcome analysis
We used public transcriptomic mRNA data (GEO DataSet, accession number: GDS3592) from non-transformed isolated human epithelial ovarian cells and ovarian carcinoma cells to identify deregulated genes. Affymetrix CEL files were downloaded and analyzed with Transcriptome Analysis Console (TAC) Software, developed by Affimetrix. Normalization was performed using MAS5.
Genes that were upregulated with a minimum of 4 fold change were selected.
Functional annotation was performed with DAVID Bioinformatics Resources 6.7 and adjusted p-value <0.05 to select the enriched gene-sets. Data contained at oncomine (https://www.oncomine.org/resource/login.html) was used to confirm the upregulated genes. Copy number alterations including amplifications, deletions or mutations were evaluated using cBioportal (http://www. cbioportal.org) [18] . For the association of gene expression with clinical outcome in early stage ovarian cancer we used the Kaplan Meier (KM) Plotter Online Tool [19] . The immortal human keratinocyte cell line HACAT was growth in DMEM.
Cell Culture and drug compounds
Ovarian cancer cell lines were growth in RPMI (OVCAR3, IGROV1) and DMEM (SKOV3, OVCAR8) containing 10% fetal bovine serum (FBS). OVCAR3 and OVCAR8 tumorspheres were grown in DMEM-F12 plus BSA (0.4%), insulin (5µg/ml), bFGF (20ng/ml) and EGF (20ng/ml). All media were supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine and cells were maintained at 37ºC in a 5% C0 2 atmosphere. All cell lines used were provided by Drs J Losada and A Balmain (from the ATCC) in 2015. In addition, cells are analyzed annually by STR at the molecular biology unit at the Salamanca University Hospital.
Cell culture media and supplements were obtained from Sigma Aldrich (St.
Louis, MO). LY2603618, Alisertib, AZ3146 and Docetaxel were obtained from Selleckchem (Munich, Germany). Carboplatin was purchased from Pfizer GEP, SL. Cells were Mycoplasma free at different evaluations.
MTT, clonogenic assays and matrigel embedded 3D cultures
Dose-response and synergy studies were assessed by MTT screening assay.
Ovarian cancer cell lines were seeded in 48-multiwell plates (10.000 cells per well) and treated with the indicated compounds and doses for the indicated times. To determine cell proliferation, MTT was added to the wells for 1h at 37ºC (0.5 mg/ml). Then, MTT was solubilized with DMSO and absorbance was measured at 562 nm (555-690) in a multiwell plate reader (BMG labtech).
Results were plotted as the mean values of three independent experiments. 
LDH cytotoxicity assays
For LDH cytotoxicity assay, OVCAR3 and OVCAR8 were seeded in a 48-multiwell plate (10.000 cells per well) and, the following day, treated with Alisertib, LY2603618 and the combination of both drugs for 72 hours. Then, LDH activity was evaluated following manufactured instructions (Pierce LDH Cytotoxicity Assay Kit, ThermoFisher Scientific).
Flow cytometry analysis
For cell cycle experiments, OVCAR3, OVCAR8 and SKOV3 were seeded and 24h later synchronized with double thymidine block (2 mM). Briefly, cells were exposed to thymidine for 18h, and then, after recovering in thymidine free medium for 9h, a second exposure was performed for another 18h. Then, cells were washed and treated with Alisertib, LY2603618 or the combination of them for 24h. Non-treated cells were used as a control. 
Caspase-3 activity assays
Ovarian cancer cell lines OVCAR3 and OVCAR8 were lysed in apoptosis lysis buffer (20 mM Tris, 140 mM NaCl, 10 mM EDTA, 10% glycerol, 1% NP40, pH For MTS proliferation assays (MTS Cell Proliferation Assay Kit, Abcam), OVCAR3 and OVCAR8 TS were seeded in a 48-multiwell plate (10.000 cells per well) and treated with Alisertib, LY2603618, Docetaxel and Carboplatin for 72h. Then, MTS reagent was added to culture media for 1h, following supplier manufactured instructions, and the absorbance was measured at 490nm.
Statistical analysis
All experiments were performed at least three times. Student t-test was used to determine significant statistical differences. Two-ways Student's test was used for the statistical analyses (p0.05*, p0.01**, p0.001***). 
Results
In silico transcriptomic analyses identify druggable kinases in ovarian cancer
To identify molecular functions dysregulated in ovarian tumors, we performed transcriptomic analyses guided by functional genomics. We used a public dataset containing information from non-transformed isolated human epithelial ovarian cells and ovarian carcinoma cells (GEO DataSet accession number: GDS3592). Using a minimum fold change of four we select 2925 genes ( Figure   1A ). Functional analyses identified deregulation of relevant functions including cell differentiation, response to stress or cell cycle, among others ( Figure 1A ).
Taking in consideration the relevant role of cell cycle mediators in cancer, we searched for druggable kinases contained within this function, identifying only four druggable genes: AURKA, AURKB, CHEK1 and TTK/MPS1. Figure 1B shows these genes with the fold change identified in our analyses (GDS3592) and the confirmation performed using data contained at Oncomine (www.oncomine.org). All genes included within the cell cycle function are described in Supplementary table 1.
Before evaluating compounds against these kinases, it was relevant to know if molecular alterations of these genes exist in ovarian tumors. To do so we used data from 311 tumors contained at cBioportal [18] observing that AURKA was amplified in 8.7% of tumors and CHEK1 in 3,9%. TTK/MPS1 was amplified in 1.6% and AURKB was not amplified ( Figure 1C) . 
SKOV3. To assess the effect on proliferation of new drugs targeting these kinases we used three compounds: LY2603618 against the CHEK1 [20, 21] ; Alisertib (MLN8237) against AURKA [22, 23] ; and AZ3146 against TTK/MPS1
[24, 25]. The most anti-proliferative effect was observed for LY2603618 and Alisertib, targeting AURKA and CHEK1 ( Figure 1D and E) . We observed less activity for AZ3146 ( Figure 1F ). To evaluate the therapeutic index of LY2603618
and Alisertib we used the non-transformed cell line model HACAT, observing that the doses required to produce anti-proliferative effect were higher than in tumoral ones (Supplementary Figure 1) .
Targeting of Aurora Kinases A synergizes with CHEK1 inhibition
Next, we decided to combine inhibitors of CHEK1 and AURKA together as were the most active compounds in our cellular screening. Combination of LY2603618 with Alisertib was synergistic at most of the doses tested ( Figure   2A ). Increasing doses of LY2603618 augmented the effect of a fixed dose of Alisertib in OVCAR8 and OVCAR3 ( Figure 2B ). Studies using semi-solid media with matrigel, showed a similar effect with the combination, being the effect more evident in OVCAR3 ( Figure 2C ). We also explored the effect of the combination using clonogenic assays showing similar results (Supplementary Figure 2A) . Finally, we confirmed the cytotoxic effect by performing a LDH assay of the combination compared with each agent alone in OVCAR3 and OVCAR8 (Supplementary Figure 2B) .
Combination of both compounds induces cell cycle arrest leading to apoptosis
Given the fact that the combination of both compounds inhibited cell proliferation when evaluated in different models; we decided to explore if this effect was due to a cell cycle arrest or an induction of apoptosis. To do this, we used the two most sensitive cell lines, OVCAR3 and OVCAR8. Treatment with Alisertib showed a profound arrest at the G2/M phase, while treatment with LY2603618 showed a slight increase at G1 that was more evident in OVCAR8 ( Figure 3A) . Treatment with the combination produced an arrest at G2/M in OVCAR8; effect that was less evident in OVCAR3 and SKOV3 ( Figure 3A and Supplementary Figure 3) .
The biochemical evaluation of G2/M components showed an increase in pH3 in OVCAR8 at 12 hours, indicative of arrest in M ( Figure 3B ). This effect was less seen in OVCAR3. No clear modifications of p21 and p27 were observed with the combination (Supplementary Figure 3) .
To confirm the effect of Alisertib and LY2603618 on Aurora Kinases and CHEK1, we performed western blot studies with these compounds given alone or in combination at 12 and 24 hours. LY2603618 was able to inhibit the phosphorylation of CHEK1 and Alisertib did not affect other Aurora Kinase isoforms like AURKB or AURKC. Treatment with nocodazole arrested cells at G2 ( Figure 3C ).
To analyzed the effect of the combination on the mitotic process we evaluated the percentage of aberrant mitotic spindles. Combination of LY2603618 and
Alisertib showed an increase in the formation of aberrant spindles that was more profound in OVCAR8, in line with the arrest observed at G2/M and the increase in pH3 ( Figure 3D ). Supplementary figure 4A shows random images in OVCAR3 and OVCAR8 of aberrant mitotic spindles for each treatment. Next, we evaluated the effect of this combination on cell death. As can be seen in figure 4A , administration of the combination induced apoptosis in both OVCAR3 and OVCAR8. Treatment with the pan-caspase inhibitor Z-VAD-FMK partially reduced the induction of apoptosis, demonstrating that some of the apoptosis induction was mediated by caspases ( Figure 4B ). This observation was further confirmed by the evaluation of caspase 3 activity in OVCAR3 and OVCAR8 (Supplementary Figure 4B) The biochemical analysis demonstrated that the combination increased pH2AX in both cell lines, a marker of DNA damage and did not induce PARP degradation ( Figure 4C ).
The combination of Alisertib and LY2603618 affects stem cell like properties
As stem-cells play a major role in ovarian relapse, we decided to explore the effect of the combination on stem cell properties. We first explored expression of the stem cell biomarkers CD44 and CD133 in OVCAR3 and OVCAR8 after treatment with Alisertib, LY2603618 and the combination in the overall population of adherent cells. We observed that combination slightly reduced surface expression of CD44 and CD133 when compared with each agent given alone ( Figure 5A and Supplementary Figure 5 ). As cells grown as tumorspheres (TS) better recapitulate stem cell properties [26], we evaluated the effect of each drug alone or the combination on secondary TS formation. Figure 5B shows enrichment in the stem cell markers CD44 and SOX2 on OVCAR3 and OVCAR8-derived TS, confirming that derived TS are an appropriate model to evaluate the effect of drugs. The combination was able to reduce the formation of TS in a greater manner than when each agent was given alone ( Figure 5C ). 
The combined inhibition synergizes with chemotherapies
To translate our findings to the clinical setting we evaluated the synergistic interaction of LY2603618 and Alisertib alone or when given with docetaxel and carboplatin. We decided to use these chemotherapies as platinum-based agents and taxanes are the main treatment in ovarian cancer. The combination augmented the effect of each agent given alone ( Figure 6A ), and showed a synergistic interaction for most of the doses used in three cell lines, SKOV3, OVCAR3 and OVCAR8 (Supplementary Figure 1) . These data demonstrate that the administration of LY2603618 and Alisertib could have a potential translation to patients if given with standard chemotherapy.
Association of Aurora Kinase A and CHEK1 gene expression with outcome
Finally, we decided to evaluate the association of these kinases with clinical outcome using public transcriptomic data [19] . The concomitant expression of Aurora Kinase A and CHEK1 was linked to detrimental progression free survival (PFS) and overall survival (OS) in early stage ovarian cancer patients ( Figure   6B ). These data confirmed the implication of these kinases in the oncogenic phenotype of ovarian tumors.
Discussion
In the present article we describe a synergistic antitumoral effect between AURKA and CHEK1 inhibitors in ovarian cancer. We used an in silico analysis to identify relevant functions that can be pharmaceutically inhibited. These studies permitted the identification of some kinases that regulate cell cycle progression. Of note, the upregulated genes identified in this small dataset were confirmed with data contained at Oncomine, a database that includes a large number of patients. Moreover, some of these genes participate in pathways that are involved in the pathophysiology of this tumor [11] . By using public data from TCGA, we identified that AURKA and CHEK1 were amplified in 8.7% and 3.9% of ovarian tumors, respectively; providing the rational for exploring agents against these kinases. Although our in silico approach is valid, confirmation of our results using data from a prospective cohort of patients would reinforced the findings.
Next, we aimed to explore agents against the identified proteins. Interestingly Alisertib, a kinase inhibitor against AURKA, and LY2603618 a CHEK1 inhibitor, were the most active compounds compared with the TTK/MPS1 inhibitor AZ3146. It is relevant to mention that some Aurora Kinases, as well as other FOXM1-controlled cell cycle proteins such as CDC25, cyclin B and PLK1, have been reported to be overexpressed in ovarian cancer [11] . In addition, among the combination of agents used, AURKA inhibition synergized with CHEK1 inhibitors, and this was not observed when combining other agents. Alisertib is an AURKA inhibitor that is currently at its late stage in clinical development in non-small cell lung cancer (NSCLC) and has shown activity in several solid tumors [12, 13] . CHEK1 inhibitors including LY2603618 are in early stage clinical development in different tumor types, mainly NSCLC [21] .
When evaluating the mechanism of action, Alisertib induced arrest at the G2/M phase as it is an agent that affects kinases involved in the formation of the Combination of both agents increased G2/M arrest at different levels, and produced a profound induction of apoptosis. This finding is of remarkable interest as each agent alone showed a cytostatic effect, but the combination was cytotoxic, a desirable effect when treating cancer patients.
As most of cancer deaths are associated with tumor relapses and tumor cells with stem cell properties are involved in this process, we decided to explore the effects of the combination on the stem cell population. The combination of both compounds reduced the expression of stem cell biomarkers in a greater magnitude than each agent alone. Moreover, self-renewal capability was also altered, as observed when evaluating secondary TS formation after treatment.
Some studies have described the effect of the individual inhibition of these kinases on the stem cell properties [27, 28] . However, this is the first time that this effect has been described with the combination.
Translating preclinical drug combinations to potential uses in the clinical setting is a main goal. To do so we explored the activity of this combination with standard chemotherapy used in ovarian cancer, including docetaxel and carboplatin. OVCAR3 and OVCAR8 showed different sensitivity to docetaxel and carboplatin, but administration of LY2603618 and Alisertib increased the activity of each agent given alone. Globally, these results open the possibility to further explore these combinations in the clinical setting. data demonstrate the oncogenic activity of these kinases in ovarian cancer.
Secondly, molecular analyses of the pathways in which these genes participate may be used to select patients sensitive to these agents. Of note, administration of targeted agents against amplified genes has shown clinical utility as is the case for HER2 in breast cancer [29] .
In conclusion, we describe a novel combination of agents for the treatment of ovarian cancer with potential implications in the clinical setting. Amplification of AURKA and CHEK1 is observed in more than 12% of the cases, opening the possibility to develop this combination in patients with amplifications of these genes.
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